NorDiag to Buy DNA Sample Prep Firm Genpoint for $13.3M | GenomeWeb
NEW YORK (GenomeWeb News) – Norwegian cancer diagnostics company NorDiag has signed a deal to buy DNA sample prep company Genpoint, also based in Norway, in a stock deal worth NOK 83.3 million ($13.3 million), NorDiag said last week.
 
NorDiag said the acquisition will expand its cancer and infectious diagnostics line and will help speed its colorectal cancer test to the market.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.